Treatment

Assessment of severity of ICD (impulse control disorders) clinical trials

1 indexed studies · 1 currently recruiting

Not yet recruiting
Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
This study is looking into a new medication called pimavanserin for people with Parkinson's disease who also experience impulse control disorders (ICDs). The aim is to see if this medicine can help manage these behaviours safely and effectively.
For: Parkinson Disease
France